Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 38,5 M
EBIT 2015 -3,26 M
Net income 2015 -7,92 M
Finance 2015 25,4 M
Yield 2015 -
Sales 2016 63,5 M
EBIT 2016 8,12 M
Net income 2016 -2,15 M
Debt 2016 14,6 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 7,99x
EV / Sales 2016 5,47x
Capitalization 333 M
More Financials
Company
IGI Laboratories, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's... 
Sector
Pharmaceuticals
Calendar
07/23Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
06/30 IGI LABORATORIES : Announces Fifth ANDA Submission Of 2015
06/09 IGI LABORATORIES : Announces Fourth ANDA Submission of 2015
05/28 IGI LABORATORIES : Announces Third ANDA Submission Of 2015
05/27 IGI LABORATORIES : Updates Business Outlook
05/12 IGI LABORATORIES : To Present At Bank Of America Merrill Lynch 2015 Health Care ..
05/06 IGI LABORATORIES : To Present At Deutsche Bank 40th Annual Health Care Conferenc..
04/28 IGI LABORATORIES : Announces Second ANDA Submission Of 2015
04/28 IGI LABORATORIES : Announces First Quarter 2015 Results
More news
Sector news : Pharmaceuticals - NEC
08:34a NOVO NORDISK A/S : A/S : - Share repurchase programme
08:31a TEVA PHARMACEUTICAL : Launches Generic Aggrenox® Capsules in the United States
08:15a TEVA PHARMACEUTICAL : and Xenon Provide Update on TV-45070 Phase 2b Study in Ost..
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions